Abstract 2092P
Background
Breast cancer tops the list of cancer types prevalent in Algeria, with more than 14,000 new cases recorded each year, of which a significant rate appears before the age of 40. it is aggressive and requires the use of chemotherapy known to be associated with immediate and long-term toxicities, which may affect the quality of life of cancer survivors. One of the chemotherapy-related long-term toxicities among premenopausal patients is hormonal changes with ovarian failure, chemotherapy-related amenorrhoea (CRA) and early menopause witch may lead to bone loss.The objectives were to evaluate bone mineral density (BMD) and to determine potential associated factors for bone loss among young premenopausal patients after adjuvant chemotherapy.
Methods
We included premenopausal Algerian aged <45 years who had received adjuvant chemotherapy. At study entry, background demographics, cancer characteristics and menstrual history were collected; BMD was measured by DXA in trabecular and cortical sites. Factors associated with reduced BMD and fracture risk were analyzed.
Results
A total of 83 patients were evaluated.The median age at the time of diagnosis of breast cancer is 37 years old, while the age at entry into the study is 43 years old. The median BMDs for femoral neck (FN) was 1.02 g/cm2 and lumbar spine (LS) 0.95 g/cm2; 37.2% had abnormal Z-scores (defined as ≤–1) and 44.7% had osteopenia/osteoporosis of either FN or LS. On multivariate analyses, factors that were identified correlated with bone loss (low BMD) are: young age at cancer diagnosis (OR [95% CI] = 2.103 [1.091–3.181), low Vitamine D level (OR = 2.254 [1.541–4.637]), low BMI (OR = 2.56 [1.599–2.907]), longer interval since last adjuvant treatment (OR for LS: 2.217 [1.250–4.357]), and having received adjuvant tamoxifen (OR = 1.752 [1.243–3.841]).
Conclusions
This study highlights that bone loss is prevelent condition in early breast cancer survivors who are on or after chemotherapy. About 44.7% of early breast cancer survivors found to have bone loss .To prevent bone fracture; certain factors associated with this condition deserve to be detected and corrected.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
HCA Hospital University of Algiers Algeria.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
2065P - Communication on the first medical oncology appointment: What do cancer patients want?
Presenter: Rodrigo Vicente
Session: Poster session 06
2066P - Evaluation of the quality and reliability of ChatGPT and Perplexity's responses about rectal cancer
Presenter: Ozan Yazici
Session: Poster session 06
2067P - Influence of psychiatric disorders on survival in patients with lung cancer: Real-world data
Presenter: Tomi Kovacevic
Session: Poster session 06
2068P - Perspectives and concerns on sexuality among adolescents and young adults treated for testicular germ cell tumour: The PRICELESS-study - A qualitative study
Presenter: Danielle Zweers
Session: Poster session 06
2069P - QoL changes of caregivers during first-line palliative chemotherapy for patients with incurable cancer
Presenter: Nobumichi Takeuchi
Session: Poster session 06
2070P - Assessment of healthy lifestyle habits in breast cancer patients
Presenter: Juan Cristobal Sanchez
Session: Poster session 06
2071P - Identification of top issues and concerns of cancer patients in Korea on social media
Presenter: Joo Han Lim
Session: Poster session 06
2072P - Topical application of mixed agents to reduce oral mucositis during radiotherapy in post operated head and neck cancer
Presenter: Chandra Prakash
Session: Poster session 06
2073P - Medical cannabis: A potential effective treatment for chemotherapy-induced peripheral neuropathy (CIPN)
Presenter: Ravit Geva
Session: Poster session 06
2074P - Oral cannabidiol for prevention of chemotherapy-induced peripheral neuropathy
Presenter: Sebastian Nielsen
Session: Poster session 06